-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Food and Drug Administration showed that Haisco’s application for the listing of avanafil tablets (acceptance numbers: CYHS1900563, CYHS1900564) submitted by registration classification 3 (domestic applicants imitated overseas listings but the original research was not listed domestically) has been At the "approval" stage, it is expected that the NMPA will approve the listing in the near future, and it will be the first imitation of this variety after listing.
Avanafil is a generic drug product developed by Hesco.
According to the "Guidelines for the Management of Erectile Dysfunction (2018) issued by the American Urological Association (AUA)", the recommended oral PDE5 inhibitors for ED mainly include sildenafil, tadalafil, vardenafil, and avana non.
Avanafil tablets were originally authorized by Japan’s Tanabe Mitsubishi Pharmaceuticals Co.
Currently, Shanghai Huilun Jiangsu Pharmaceutical Co.
There are three types of PDE5 inhibitors currently on the market in the domestic ED market: tadalafil, sildenafil and vardenafil, among which Eli Lilly's tadalafil and Pfizer sildenafil account for the main market shares.
